<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20241028063524N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-12-27</date_registration>
      <primary_sponsor>University of Nigeria Teaching Hospital,Enugu,Nigeria</primary_sponsor>
      <public_title>Comparison of  the effects of intravenous ondansetron, paracetamol and both drugs in prevention of post-dural puncture headache following spinal anaesthesia for caesarean section;A double-blind randomised controlled trial.</public_title>
      <acronym>PDPHT</acronym>
      <scientific_title>Comparison of  the effects of intravenous ondansetron, paracetamol and both drugs in prevention of post-dural puncture headache following spinal anaesthesia for caesarean section;A double-blind randomised controlled trial.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-02-01</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>176</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/80639</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: Already described in the randomization section, Randomization description: The randomization of  176 pregnant women  will be accomplished utilizing a computer-generated randomization schedule (Stat-Trek Generator), and placed into consecutively numbered, opaque, sealed envelopes. The eligible women will be assigned by means of these computer-generated random numbers into 4 sample groups; intervention group A ( will receive Ondansetron alone), intervention group B(will receive Paracetamol alone), intervention group C( will receive combination of ondansetron and paracetamol) and control group D(will receive water for injection) .Thus, once the patient is deemed eligible and has given informed consent, she will be assigned a sequential study number. Block randomization of all eligible consenting patients will be done using computer generated random sequence and a randomization ratio of 1:1:1: 1. Upon enrolment, an opaque envelope containing the patient enrolment number and assignment to any of the groups,will be opened and the unique number placed on the patient’s antenatal card. Each participant will be assigned a unique subject number for identity and confidentiality, Blinding description: The participants and the outcome assessors will not know which injection  will be given to any of the participants.</study_design>
      <phase>3</phase>
      <hc_freetext>Post-dural puncture headache  is a headache that develops within 5 days after dural puncture which worsens in an upright position and improves with lying down and accompanied by neck stiffness, tinnitus, photophobia, and nausea..</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A:This group will receive 8mg and 600mg of intravenous ondansetron and paracetamol  respectively. Intervention 2: Intervention group B will receive 8mg of intravenous ondansetron. Intervention 3: Intervention group C will receive 600mg of intravenous paracetamol. Intervention 4: Control group D will receive water for injection (placebo).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The data will be provided only on request.

When:
It will be provided after publication of the project and last for 2 years

To whom:
It will be provided to the publishing journal

Conditions:
For secondary analysis of the data and for understudy of the data by another researcher.

Where to obtain:
The journal that will publish the research work or by contacting Prof. Leonard O. Ajah  through leonard.ajah@unn.edu.ng

How to obtain:
It requires writing the corresponding author and stating the aim of the request of the data

Comments:
Already stated above</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr . Ogwueleka, Chukwudubem Vitalis</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ituku-Ozalla</address>
        <city>Enugu</city>
        <country1>Nigeria</country1>
        <zip>40001</zip>
        <telephone>+234 806 902 4516</telephone>
        <email>dubemogwueleka@gmail.com</email>
        <affiliation>University of Nigeria Teaching Hospital,Enugu,Nigeria</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leonard Ajah</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>University of Nigeria</address>
        <city>Enugu</city>
        <country1>Nigeria</country1>
        <zip>400001</zip>
        <telephone>+234 803 392 0789</telephone>
        <email>leonard.ajah@unn.edu.ng</email>
        <affiliation>University of Nigeria Teaching Hospital,Enugu,Nigeria</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Nigeria</country2>
      <country2>Nigeria</country2>
      <country2>Nigeria</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. Booked patient at term attending antenatal care at the study centers.
18 – 40-year-old.
ASA I and II parturients undergoing elective caesarean section under spinal anaesthesia.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Patients with known contraindication to spinal anaesthesia
Allergy to the study drugs
Patients with comorbidities like pregnancy induced hypertension, gestational diabetes mellitus, coronary artery disease or heart disease
Patients taking drugs like selective serotonin receptor inhibitors (SSRIs)
Patients converted into general anaesthesia</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>082.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Delivery by elective caesarean section</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A:This group will receive 8mg and 600mg of intravenous ondansetron and paracetamol  respectively.</i_keyword>
      <i_keyword>Intervention group B will receive 8mg of intravenous ondansetron</i_keyword>
      <i_keyword>Intervention group C will receive 600mg of intravenous paracetamol</i_keyword>
      <i_keyword>Control group D will receive water for injection (placebo).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary outcome measure will be the incidence of  post dural puncture headache within 24 hours following caesarean delivery. Timepoint: At 6,12,18 and 24 hours post-caesarean section. Method of measurement: This will be assessed using the visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Maternal complications (spinal anaesthesia induced hypotension, intra operative and post operative nausea and vomiting). Timepoint: 1 hour,6 hours,12 hours,18 hours,24 hours. Method of measurement: Blood pressure check and report of any incidence of nausea and vomiting.</sec_outcome>
      <sec_outcome>Neonatal complications (Apgar scores at 1 and 5 min, the need for cardiopulmonary resuscitation and admission to the neonatal intensive care unit (NICU) during the first 24 hours after delivery will be assessed too). Timepoint: 1 minute,5 minutes, 24 hours. Method of measurement: APgar scoring and report of any incidence of the above interventions.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>University of Nigeria Teaching Hospital,Enugu,Nigeria</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-11-27</approval_date>
        <contact_name>University of Nigeria Teaching Hospital Research and Ethics Committee</contact_name>
        <contact_address>Ituku-Ozalla Enugu Enugu Nigeria</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
